Sagimet Biosciences Inc.
NASDAQ:SGMTBiotechnology
+$0.09 today
- Market cap
- $711.15M
- Beta
- 3.44
- P/E (TTM)
- -5.0
- EPS (TTM)
- -$1.34
Volume 0.93M
Average 1.49M
SGMT Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Sagimet Biosciences Inc.NASDAQ: SGMT
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 43.4% from a year ago
Cash & equivalents stood at $36.63M at the end of Q1 FY2026, down 43.4% from a year earlier and up 4.6% from the prior quarter. Over 3 fiscal years it compounded at +505.2% a year.
Context
- Cash & equivalents amounted to 34.0% of total assets at the end of Q1 FY2026, down 10.3 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -43.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 35.02M USD
- Year-over-year change
- -53.8%
- 4-year CAGR
- -11.4%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 35.02M | -53.8% |
| FY2024 | 2024-12-31 | 75.84M | +0.9% |
| FY2023 | 2023-12-31 | 75.14M | +47456.3% |
| FY2022 | 2022-12-31 | 158K | -99.7% |
| FY2021 | 2021-12-31 | 56.73M | — |
Cash & Equivalents vs competitors
How SGMT compares with its peers on the latest reported figures
- SGMT's Mar 2026 cash & equivalents of $36.63M is the 9th highest of the 11 companies compared; the peer median is $62.49M.
- Its year-over-year change of -43.4% is the lowest of 11, against a peer median of +22.3%.
- Cash & equivalents amounts to 34.0% of total assets for SGMT, versus a peer median of 34.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
ZURAZura Bio Limited | Mar 2026 | $225.59M | +32.3% | +311.8% | 98.7% |
| Mar 2026 | $211.38M | -2.6% | -16.2% | 86.1% | |
| Mar 2026 | $88.91M | +45.7% | +15.7% | 40.0% | |
| Mar 2026 | $79.32M | -33.6% | -47.1% | 29.7% | |
| Mar 2026 | $76.44M | +12.7% | +26.0% | 22.8% | |
| Mar 2026 | $48.54M | -22.8% | -30.4% | 43.9% | |
| Mar 2026 | $47.32M | +31.9% | +21.0% | 0.0% | |
| Mar 2026 | $43.31M | -42.1% | -12.9% | 19.7% | |
SGMTSagimet Biosciences Inc. | Mar 2026 | $36.63M | -43.4% | +505.2% | 34.0% |
| Mar 2026 | $31.12M | +32.9% | +3.7% | 13.2% | |
| Mar 2026 | $28.08M | +115.7% | -5.4% | 84.8% | |
| Peer median (excluding SGMT) | $62.49M | +22.3% | -0.9% | 34.9% | |
Competitors are the stored peer set for SGMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Sagimet Biosciences Inc.
NASDAQ:SGMT
Intrinsic Alpha fair value
Locked
Current Price
$10.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.